MG
NVO

Marex Group’s Novo Nordisk NVO Stock Holding History

Marex Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.67M Sell
100,000
-50,000
-33% -$2.37M 0.02% 253
2025
Q4 		$7.63M Buy
+150,000
New +$7.67M 0.05% 178

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Marex Group's NVO Position: Q1 2026 in Review

Marex Group reduced its Novo Nordisk (NVO) stake by 30% in Q1 2026, selling an estimated $14.3M and leaving 703,501 shares worth $25.9M. The position accounts for 0.16% of the portfolio, ranked #115.

Marex Group first reported a position in NVO in Q2 2024 and has held it in 8 quarters since. The position peaked at $51.2M in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Marex Group held 703,501 shares of Novo Nordisk worth $25.9M as of Q1 2026.
  • Marex Group sold 302,212 Novo Nordisk shares in Q1 2026, an estimated $14.3M.
  • Novo Nordisk made up 0.16% of Marex Group's portfolio in Q1 2026, its #115 holding.
  • Marex Group first reported a position in Novo Nordisk in Q2 2024 and has held it in 8 quarters since.
  • Marex Group's Novo Nordisk position peaked at $51.2M in Q4 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.